CTOs on the Move

Walking Fish Therapeutics

www.walkingfishtx.com

 
Walking Fish Therapeutics, Inc. is a privately held biotechnology company discovering and developing innovative therapeutics that harness the power of B cells as protein factories and immune modulators. Walking Fish has created a broad technology platform addressing enzyme replacement therapies, oncology, autoimmune disease, and recombinant antibody production. The company`s first program, WFX-001, employs B cells as protein factories to generate a deficient enzyme in Fabry disease. Founded in 2019 by Lewis (Rusty) Williams, MD, PhD, the former CSO of Chiron, co-founder of Cor Therapeutics and founder and Chief Executive Officer of Five Prime Therapeutics, the company has assembled a diverse ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.walkingfishtx.com
  • 450 East Jamie Court Suite 300
    South San Francisco, CA USA 94080
  • Phone: 650.392.0422

Executives

Name Title Contact Details
Nallakkan Arvindan
Chief Technology Officer Profile

Similar Companies

SENN CHEMICALS

SENN CHEMICALS is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.

PHC Holdings

This is the website of PHC Holdings Corporation, which is a global innovator in healthcare solutions.

ReCept Pharmacy LP

ReCept Pharmacy LP is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.